Independent fund research. Built on SEC filings.

How we research funds

Mutual fund · Health Care Sector · John Hancock

Health Sciences Trust Series II (JAFKX)

Ticker JAFKX · · Holdings as of Jun 30, 2026

Expense ratio
1.24%$124/yr per $10k
5-yr return
+3.9%annualized
1-yr return
+19.2%as of Dec 2025
Net assets
$251.3Mall share classes
Holdings
173

Bottom line

Is JAFKX a good fund? The bottom line

JAFKX is the Series II share class of Health Sciences Trust, an actively managed health care sector mutual fund from John Hancock.

Its expense ratio is 1.24% — about $124 a year on every $10,000 invested, more expensive than 71% of health care sector funds we track.

It returned +19.2% over one year, +3.9% a year over five years, +8.5% a year over ten (as of Dec 31, 2025, per its prospectus).

With $251 million in net assets and 173 holdings, its largest position is Eli Lilly and Company (14.3%) and the top 10 make up 48.3% of the portfolio.

The closest lower-cost alternative we found is XLV (0.08%, 80% top-holdings overlap).

What to watch

  • Expensive for its category (1.24%)
  • 12b-1 marketing fee of 0.25% a year

Updated Nov 19, 2026

What JAFKX invests in

To seek long-term capital appreciation.

Under normal market conditions, the fund invests at least 80% of its net assets (plus any borrowings for investment purposes) in common stocks of companies engaged, at the time of investment, in the research, development, production, or distribution of products or services related to health care, medicine, or the life sciences (collectively, health sciences). (The fund will provide written notice to shareholders at least 60 days prior to a change in its 80% investment policy.) While the fund may invest in companies of any size, the majority of its assets are expected to be invested in large- and mid-cap companies. The subadvisors portfolio managers divide the health sciences sector into four main areas: pharmaceutical companies, health care services companies, medical products and devices providers, and biotechnology firms. Their allocation among these four areas will vary depending on…

From the fund's prospectus (filed Apr 15, 2026).

JAFKX performance

Average annual total returns
1 yr5 yr10 yr
JAFKX+19.2%+3.9%+8.5%
Health Care Sector median+14.5%+4.2%+7.9%

Source: Fund prospectus, as of Dec 31, 2025

Full JAFKX performance history →

What JAFKX costs

On a $10,000 investment, JAFKX's 1.24% expense ratio costs about $124 a year. The prospectus estimates $1,510 in total costs over 10 years (assuming 5% annual returns). The median health care sector fund charges 0.96%.

See the full JAFKX fee table →

JAFKX top 10 holdings

#Holding% of fund
1Eli Lilly and Company LLY US14.30%
2Johnson and Johnson JNJ US6.33%
3UnitedHealth Group Incorporated UNH US5.95%
4AbbVie Inc. ABBV US5.28%
5Merck and Co. Inc. MRK US4.21%
6Gilead Sciences Inc. GILD US2.95%
7Thermo Fisher Scientific Inc. TMO US2.67%
8Vertex Pharmaceuticals Incorporated VRTX US2.38%
9Bristol-Myers Squibb Company BMY US2.22%
10Abbott Laboratories ABT US2.00%

Source: SEC Form N-PORT, period ended Jun 30, 2026

The top 10 make up 48.3% of the fund. See all top 25 holdings and asset mix →

Alternatives to JAFKX

Closest equivalent at other fund companies
FamilyFundExpense ratioOverlap
SPDR (State Street)XLV State Street(R) Health Care Select…0.08%80% Compare
FidelityFHLC Fidelity MSCI Health Care Index ETF0.084%78% Compare
VanguardVHT Vanguard Health Care Index Fund0.09%79% Compare
iSharesIYH iShares U.S. Healthcare ETF0.37%77% Compare
J.P. MorganJDOC JPMorgan Healthcare Leaders ETF0.65%58% Compare
SchwabSWHFX Schwab Health Care Fund0.8%73% Compare

More funds like JAFKX →

JAFKX FAQ

What is the expense ratio of JAFKX?
JAFKX's expense ratio is 1.24%, which works out to about $124 a year for every $10,000 invested. The prospectus estimates total costs of $1,510 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is JAFKX a good investment?
It depends on your goals, but the data points to: expensive for its category (1.24%); 12b-1 marketing fee of 0.25% a year. This is general information, not personalized advice.
What does JAFKX hold?
JAFKX's largest holdings are Eli Lilly and Company (14.3%), Johnson and Johnson (6.3%), UnitedHealth Group Incorporated (5.9%), AbbVie Inc. (5.3%), Merck and Co. Inc. (4.2%). It holds 173 positions in total as of Jun 30, 2026 (SEC Form N-PORT).
What is JAFKX's 5-year return?
JAFKX returned +3.9% a year over the five years ending Dec 31, 2025, and +8.5% a year over ten years. Past performance does not guarantee future results.
What is a cheaper alternative to JAFKX?
XLV (State Street(R) Health Care Select Sector SPDR(R) ETF) overlaps about 80% with JAFKX and charges 0.08%.
Who manages JAFKX?
JAFKX is offered by John Hancock through John Hancock Variable Insurance Trust.